Erratum to “Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1063-1075]
Saved in:
Main Authors: | Kiyotaka Uchiyama, Daisuke Kamano, Tomoki Nagasaka, Eriko Yoshida Hama, Ryoichi Shirai, Rena Sumura, Ei Kusahana, Akane Yanai, Takashin Nakayama, Takahide Kimura, Rina Takahashi, Takahiro Kasai, Takaya Tajima, Koji Hosoya, Tatsuhiko Azegami, Shintaro Yamaguchi, Jun Yoshino, Jun Ito, Matsuhiko Hayashi, Takeshi Kanda, Yoshitaka Ishibashi, Naoki Washida, Hiroshi Itoh, Kaori Hayashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-07-01
|
Series: | Kidney International Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024925003274 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes
by: Liliana Italia De Rosa, et al.
Published: (2025-08-01) -
Response to the Letter to the Editor Entitled “Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes”
by: Neera K. Dahl, et al.
Published: (2025-08-01) -
Dietary and lifestyle interventions in ADPKD – a review of current literature
by: Martyna Skweres, et al.
Published: (2025-07-01) -
PubChem BioAssays 1063: A Poorly Exploited Source of New Antileishmanial Compounds
by: Sergio Sifontes-Rodríguez, et al.
Published: (2025-01-01) -
Characterizing the ADPKD-IFT140 Phenotypic Signature With Deep Learning and Advanced Imaging Biomarkers
by: Ahmad Ghanem, et al.
Published: (2025-08-01)